In ER-positive HER2-negative breast cancer, Ki-67 should be tested in all cases according to 61% of the panel, while 30% would only order Ki67 if chemotherapy is considered and a genomic signature is not available (79, 80). This evidence concerns the gene ESR1 and breast cancer.